Navigation Links
SemBioSys announces second quarter 2008 financial and operational results
Date:8/5/2008

Canadian Biotechnology Company hits key insulin and Apo AI(Milano)

milestones

TSX symbol: SBS

CALGARY, Aug. 5 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced its 2008 second quarter financial and operational results.

Highlights

Insulin Program

- Submitted an Investigational New Drug Application (IND) for

safflower-produced insulin to the U.S. Food and Drug Administration

(FDA), subsequent to the end of the quarter.

- Met with the European Medicines Agency (EMEA) to agree upon a

clinical development strategy designed to allow simultaneous European

and U.S. submissions for safflower-produced insulin.

Apo AI Program

- Demonstrated that safflower-produced Apo AI(Milano) is functional, by

measuring increased cholesterol mobilization, in a widely accepted

animal model.

Botaneco

- Received $4 million in funding from Avrio Ventures Limited

Partnership in the form of a convertible debenture to accelerate the

commercialization of Hydresia(TM) products from Botaneco Specialty

Ingredients Inc., a SemBioSys subsidiary.

Outlook

SemBioSys intends to follow its recent IND application with the submission of a Clinical Trial Application (CTA) to the appropriate European authorities later in the third quarter of this year. In order to meet both FDA and EMEA requirements, the Company plans to conduct a Phase I/II clinical trial wherein safflower-produced insulin is compared to both U.S. and European-sourced reference insulin. The upcoming insulin milestone events include:

- Complete production of clinical grade insulin supply for use in Phase

I/II human clinical trials.

- Upon CTA approval, initiation of a single-doss) 11,958 153,036 (66,707) 170,985

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

65,195 361,945 95,724 534,154

------------ ------------ ------------ ------------

Net loss and

comprehensive loss

for the period (6,414,856) (3,225,371) (11,431,911) (6,453,782)

Deficit - Beginning

of period (61,176,218) (43,968,897) (56,159,163) (40,740,486)

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Deficit - End of

period (67,591,074) (47,194,268) (67,591,074) (47,194,268)

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Loss per share -

basic and diluted (0.25) (0.15) (0.44) (0.31)

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Weighted average

shares outstanding 25,937,476 22,089,356 25,936,634 20,511,557

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

SemBioSys Genetics Inc.

Consolidated Statements of Cash Flows

(Unaudited)

-------------------------------------------------------------------------

(expressed in Canadian dollars)

Three month period ended Six month period ended

June 30, June 30, June 30, June 30,

2008 2007 2008 2007

------------ ------------ ------------ ------------

$ $ $ $

Cash provided by

(used in)

Operating activities

Net loss for the

period (6,414,856) (3,225,371) (11,431,911) (6,453,782)

Add items not

affecting cash:

Amortization 580,733 241,887 1,074,567 469,945

Loss on sale of

property and

equipment - 1,483 - 1,483

Stock-based

compensation 175,947 186,654 355,850 365,704

Unrealized foreign

exchange loss (gain) 4,991 (128,534) 49,002 (149,544)

Non-cash interest

expense 18,288 - 37,068 -

------------ ------------ ------------ ------------

(5,634,897) (2,923,881) (9,915,424) (5,766,194)

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Change in non-cash

working capital and

other balances

related to

operations 88,886 (686,470) 298,802 795,297

------------ ------------ ------------ ------------

Cash used in operating

activities (5,546,011) (3,610,351) (9,616,622) (4,970,897)

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Financing activities

Issuance of capital

stock - - - 15,904,488

Share issue costs - (168,939) (57,884) (1,525,478)

Issuance of

convertible debenture 4,000,000 - 4,000,000 -

Exercise of stock

options - 10,000 31,750 14,500

Repayment of

long-term debt (158,038) (191,843) (310,584) (375,812)

Proceeds from

long-term debt - - 634,900 -

Repayment of

repayable advances - - - (85,640)

------------ ------------ ------------ ------------

Cash provided by

(used in) financing

activities 3,841,962 (350,782) 4,298,182 13,932,058

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Investing activities

Proceeds on sale of

property and

equipment - 6,000 - 6,000

Acquisition of

property and

equipment (478,806) (1,973,020) (1,023,650) (2,417,836)

------------ ------------ ------------ ------------

Cash used in

investing activities (478,806) (1,967,020) (1,023,650) (2,411,836)

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Increase (decrease)

in cash and cash

equivalents (2,182,855) (5,928,153) (6,342,090) 6,549,325

Cash and cash

equivalents -

Beginning of period 16,284,778 28,805,937 20,444,013 16,328,459

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Cash and cash

equivalents - End

of period 14,101,923 22,877,784 14,101,923 22,877,784

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Supplemental

Information

Cash interest

received 224,636 308,755 325,244 912,394

Cash interest paid 25,123 47,864 53,878 99,206

Non-cash transactions

Capital items

included in

accounts payable 24,831 824,063 24,831 824,063

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

se Phase I/II clinical

trial of safflower-produced insulin in the United Kingdom in the

fourth quarter of 2008.

- Continuation of business development activities toward an insulin

partnership.

In 2007, SemBioSys successfully achieved commercial levels of both Apo AI and Apo AI(Milano) accumulation in safflower. With positive results demonstrating safflower-produced Apo AI(Milano) increased cholesterol mobilization in animals earlier this year, SemBioSys is continuing testing in animals to establish that safflower-produced Apo AI(Milano) is equivalent to microbial-produced Apo AI(Milano) with respect to plaque-remodeling and plaque regression. The upcoming milestone events include:

- Completion of in vivo efficacy studies of plaque remodeling with

safflower-produced Apo AI(Milano) followed by studies of plaque

regression using a mouse model.

- Continuation of the formal partnering process for safflower-produced

Apo AI(Milano). The Company has already initiated confidential

discussions with several potential large pharmaceutical partners.

In addition to its pharmaceutical milestones, SemBioSys also expects to collect milestone payments from Arcadia Biosciences, Inc., upon their successful commercial scale-up and market launch of High GLA Safflower Oil in late 2008 or early 2009.

Meanwhile, Botaneco is also advancing the development of its personal care ingredient products with the expansion of the commercial distribution of Hydresia(TM) and Hydresia(TM) G2. With the completion of the recent funding transaction with Avrio, along with the previously committed $2.4 million from AVAC Ltd., SemBioSys expects Botaneco to be self-financing moving forward.

"The progress we have made with our two lead pharmaceutical programs, insulin and Apo AI(Milano), over the past few months has transformed SemBioSys. We are now poised to have insulin enter the clinic later this year as the first recombinant human protein produced from safflower to advance into human trials, which addresses a component of the largest volume drug protein market in the world. The animal results we received demonstrating safflower-produced Apo AI(Milano) successfully increased cholesterol mobilization were a critical milestone for the Company. With these data in hand, we are now able to intensify our formal partnering process for Apo AI(Milano) in parallel to the execution of additional animal studies designed to show plaque remodeling and plaque regression. We are already engaged in discussions with several major pharmaceutical companies concerning this program," said Andrew Baum, president and chief executive officer of SemBioSys. "As we advanced each of our pharmaceutical programs we also made important operational progress with our subsidiary, Botaneco. The funding from AVAC and Avrio provides Botaneco with the financial independence to pursue commercial opportunities on its own, while SemBioSys focuses its resources on advancing the insulin and Apo AI(Milano) programs."

Financials

Prior to the third quarter of 2007, SemBioSys operated under one segment. During the third quarter of 2007, Botaneco completed construction of its manufacturing facility and SemBioSys began to operate in two reportable segments: (i) the Biopharmaceutical, Animal Health and Nutritional Oils segment focused on the Company's lead pharmaceutical candidates, recombinant human insulin and Apo AI(Milano) and (ii) the Specialty Ingredients segment. As of October 1, 2007, Botaneco Specialty Ingredients Inc. was established as a separate legal entity, and SemBioSys' previously dormant U.S. subsidiary, SemBioSys Inc., was renamed as Botaneco Inc.

Total revenue for the three and six-month periods ended June 30, 2008 was $62,207 and $272,234 respectively, compared with $459,407 and $1,002,195 for the corresponding periods in 2007. The difference is due mainly to a license fee payment earned from the Company's collaboration agreement with Martek BioSciences Corporation in the first half of 2007 which is partially offset by 2008 product sales revenue from Hydresia(TM) and the option payment received from INDEAR S.A.

Total expenditures for the three and six-month periods ended June 30, 2008 were $6,542,258 and $11,799,869 respectively, compared with $4,046,723 and $7,990,131 for the corresponding periods last year.

Research and development expenses for the three and six-month periods ended June 30, 2008 were $3,357,683 and $6,151,786, compared with $1,924,745 and $3,668,717 for the corresponding periods last year. The difference is primarily related to the shift in the stage of development of the Company from research to preclinical development of two major drug candidates, which requires significant external resources to advance and prepare for the upcoming clinical trials. These include increased contract research organization (CRO) costs, independent third party animal studies, preparation of GMP and cGMP material and other outsourcing costs, as well as increased personnel and the associated support costs and laboratory supplies related to preclinical activity.

General and administrative expenses for the three and six-month periods ended June 30, 2008 were $1,666,323 and $3,061,598 respectively, compared with $1,086,766 and $2,110,477 for the corresponding periods last year. The difference is mainly due to the commercial operations of Botaneco being fully established during 2008 resulting in additional increases in general and administrative costs and legal fees incurred for the Botaneco debenture financing.

Intellectual property costs for the three and six-month periods ended June 30, 2008 were $504,690 and $847,020 respectively, compared with $307,414 and $835,663 for the corresponding periods last year. The difference in costs for the three-month periods is due mainly to an increase in legal costs for patent applications for the Company's insulin program during 2008, which were partially offset by a decrease in royalty payments.

Business development costs for the three and six-month periods ended June 30, 2008 were $155,522 and $315,152 respectively, compared with $404,434 and $713,909 for the corresponding periods last year. The difference is primarily due to the shift in Botaneco's activities from essentially entirely business development related prior to the commissioning of its commercial manufacturing operations which occurred in September 2007, to now being fully operational.

Net loss for the 2008 second quarter was $6,414,856 or ($0.25) per share, compared to a net loss of $3,225,371 or ($0.15) per share for the same period last year. Net loss for the six-month period ended June 30, 2008 was $11,431,911 or ($0.44) per share compared with $6,453,782 or ($0.31) per share for the same six-month period last year. The change in net loss is primarily due to the increased commercial activities of Botaneco and the increased preclinical activities related to insulin and Apo AI.

As at June 30, 2008 the Company had cash and cash equivalents totaling $14,101,923 and a net positive working capital balance of $13,154,749 compared to $20,444,013 and $19,518,408 respectively, at December 31, 2007. Total long-term debt and convertible debentures at June 30, 2008 was $4,352,904 compared with $1,389,047 at December 31, 2007.

As at July 31, 2008 the Company had 25,938,294 common shares outstanding, 2,390,000 warrants and 2,387,269 options.

About SemBioSys Genetics Inc. (http://www.sembiosys.com)

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI(Milano), a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys and its subsidiary, Botaneco Specialty Ingredients Inc., are developing a series of non-pharmaceutical products addressing human topical, nutritional oils and agricultural biotechnology markets. More information is available and can be accessed at http://www.sembiosys.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at http://www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

Financials results included below:

SemBioSys Genetics Inc.

Consolidated Balance Sheets

(Unaudited)

-------------------------------------------------------------------------

(expressed in Canadian dollars)

June 30, December 31,

2008 2007

$ $

------------ ------------

Assets

Current assets

Cash and cash equivalents 14,101,923 20,444,013

Accounts receivable 228,300 613,912

Prepaid expenses and deposits 317,810 538,718

Inventory 743,568 426,641

------------ ------------

15,391,601 22,023,284

Property and equipment 8,969,956 9,272,415

------------ ------------

24,361,557 31,295,699

------------ ------------

------------ ------------

Liabilities

Current liabilities

Accounts payable and accrued liabilities 1,673,651 1,875,397

Short-term portion of long-term debt 563,201 629,479

------------ ------------

2,236,852 2,504,876

Deferred cost recoveries 207,527 286,596

Long-term debt 1,216,830 759,568

Convertible debenture 2,572,873 -

------------ ------------

6,234,082 3,551,040

------------ ------------

------------ ------------

Shareholders' Equity

Capital stock 70,427,920 70,396,170

Warrants 2,550,880 6,180,690

Contributed surplus 11,312,622 7,326,962

Equity component of convertible debenture 1,427,127 -

Deficit (67,591,074) (56,159,163)

------------ ------------

18,127,475 27,744,659

------------ ------------

24,361,557 31,295,699

------------ ------------

------------ ------------

SemBioSys Genetics Inc.

Consolidated Statements of Loss, Comprehensive Loss and Deficit

(Unaudited)

-------------------------------------------------------------------------

(expressed in Canadian dollars, except shares)

Three month period ended Six month period ended

June 30, June 30, June 30, June 30,

2008 2007 2008 2007

------------ ------------ ------------ ------------

$ $ $ $

Revenue

Licensing fees - 437,012 50,110 874,024

Contract research - 22,395 - 128,171

Product sales 62,207 - 222,124 -

------------ ------------ ------------ ------------

62,207 459,407 272,234 1,002,195

Expenses

Research and

development 3,357,683 1,924,745 6,151,786 3,668,717

General and

administration 1,666,323 1,086,766 3,061,598 2,110,477

Intellectual property

costs 504,690 307,414 847,020 835,663

Business development 155,522 404,434 315,152 713,909

Sales and marketing 96,621 - 249,781 -

Cost of products sold 45,534 - 317,279 -

Stock-based

compensation 175,947 186,654 355,850 365,704

Amortization 580,733 241,887 1,074,567 469,945

Cost recoveries (40,795) (105,177) (573,164) (174,284)

------------ ------------ ------------ ------------

6,542,258 4,046,723 11,799,869 7,990,131

------------ ------------ ------------ ------------

Loss before the

undernoted (6,480,051) (3,587,316) (11,527,635) (6,987,936)

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Interest income 96,649 262,962 267,507 475,195

Interest expense (43,412) (52,570) (105,076) (110,543)

Loss on sale of

property and

equipment - (1,483) - (1,483)

Foreign exchange

gain (lo
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
2. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
3. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
4. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
5. SemBioSys announces first quarter 2008 financial and operational results
6. SemBioSys receives milestone payments from AVAC Ltd.
7. SemBioSys initiates toxicology study for safflower-produced insulin
8. SemBioSys announces 2007 financial and operational results
9. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
10. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
11. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , February 9, 2016 Three-Year ... Enables Children to Take Part in Life-Changing Camp ... new initiative designed to positively affect the lives of children born ... care. --> SHPG ) is announcing a new initiative ... diseases, as well as the future of rare disease care. ...
(Date:2/9/2016)... , Feb. 9, 2016 ... Inhibitors-Pipeline Insights, 2016", report provides in depth ... development activities around the Protein-Tyrosine Phosphatase 1B ... product profiles in various stages of development ... II, Phase III and Preregistration. Report covers ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016 Should ... standard bone cement products to prevent infection after standard ... that the experts at ECRI Institute have been fielding ... Infection or Fighting Your Bottom Line?" ... Your Bottom Line?" --> While ...
(Date:2/8/2016)... , February 8, 2016 ... Private Limited, an innovation-driven oncology company developing next ... less toxic, today announced that chairman emeritus of ... invested in the company as part of the ... joining existing investors Navam Capital and Aarin Capital. ...
Breaking Biology Technology:
(Date:2/2/2016)... --Technology Enhancements Accelerate Growth of X-ray Imaging This ... computed radiography markets in Thailand , ... (TIM). It provides an in-depth analysis of ... regional market drivers and restraints. The study offers revenue ... attractiveness, both for digital and computed radiography. Market participants ...
(Date:2/1/2016)... smart wallet ( www.wocketwallet.com ) announces the launch of a new video ... Las Vegas , where Joey appeared at the Wocket ... Vegas , where Joey appeared at the Wocket booth to meet ... filmed at the Consumer Electronics Show (CES2016) in Las Vegas ... greet fans. --> --> The ...
(Date:1/22/2016)... DUBLIN , January 22, 2016 ... has announced the addition of the  ... to their offering. --> ... of the  "Global Behavioral Biometric Market ... --> Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ...
Breaking Biology News(10 mins):